Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer.
MetadataShow full item record
The emergence of mutations that confer resistance to molecularly targeted therapeutics is dependent upon the effect of each mutation on drug affinity for the target protein, the clonal fitness of cells harboring the mutation, and the probability that each variant can be generated by DNA codon base mutation. We present a computational workflow that combines these three factors to identify mutations likely to arise upon drug treatment in a particular tumor type. The Osprey-based workflow is validated using a comprehensive dataset of ERK2 mutations and is applied to small-molecule drugs and/or therapeutic antibodies targeting KIT, EGFR, Abl, and ALK. We identify major clinically observed drug-resistant mutations for drug-target pairs and highlight the potential to prospectively identify probable drug resistance mutations.
Open access locationhttps://www.sciencedirect.com/science/article/pii/S2451945618302654?via=ihub
Version of record
targeted cancer drugs
In Silico Medicinal Chemistry
Medicinal Chemistry 1 (including Analytical Chemistry)
License start date
Cell Chem Biol, 2018, 25 (11), pp. 1359 - 1371.e2